Skip to main content
. 2024 Dec 2;14(1):e240055. doi: 10.57264/cer-2024-0055

Figure 2. . 24-month total costs and projected target lesion revascularizations for the percutaneous transluminal angioplasty ‘status quo’ versus Tack-supported strategies and projected 24-month incremental QALY gain with Tack.

Comparison of quality-adjusted life year gain and costs for Tack-supported treatment strategy in non-severe and severe dissection cohorts. cost–effectiveness and QALY gain analysis of Tack-supported treatment strategy in aortic dissection cohorts.

(A) Non-severe dissection cohort. (B) Severe dissection cohort. (C) Total dissection cohort.

24M: Twenty-four months; QALY: Quality-adjusted life year.